Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.
Sigilon Therapeutics, a US-based chronic illness therapy developer based on research primarily from Massachusetts Institute of Technology (MIT), has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2015, Sigilon has built a drug development platform dubbed Shielded Living Therapeutics which it is using to create therapeutic molecules that can make up for proteins, antibodies and hormones that might be deficient or missing in a patient.
The company plans to put the IPO proceeds into a phase 1/2 clinical trial for a haemophilia A drug candidate called SIG-001, in addition to expanding its manufacturing processes for SIG-001 and SIG-005, a second candidate being developed to treat mucopolysaccharidosis type 1, a rare lysosomal storage disease.
Sigilon was co-founded by a team of researchers from MIT – Daniel Anderson, Robert Langer, Arturo Vegas and Omid Veiseh – in collaboration with José Oberholzer, who was…
